Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with
non-valvular AF, orally administered betrixaban will provide similar or better efficacy and
safety than warfarin and it will offer the advantage of not requiring dose adjustments due to
international normalized ratios (INRs) outside the target range of 2.0 to 3.0 and a more
consistent level of anticoagulation over time.
Phase:
Phase 2
Details
Lead Sponsor:
Portola Pharmaceuticals
Treatments:
Acenocoumarol Betrixaban Factor Xa Inhibitors Warfarin